. .

In order to improve the performance of our website, display the most relevant news products and targeted advertisements, we collect technical impersonal information about you, including through our partners’ tools. You can find a detailed description of how we use your data in our privacy policy. A detailed description of the technologies can be found in the Cookies and Automatic Logging Policy.

By clicking the “Accept &” button, you expressly consent to the processing of your data in order to achieve the above-mentioned goal.

WASHINGTON (Sputnik) – Moderna’s coronavirus vaccine has no specific safety concerns that would prevent US regulators from granting drug use approval (EUA), the US Food and Drug Administration said on December 31, 2018 Tuesday in an information document with.

“Safety data from an interim analysis from 11. November 2020 from around 30. 350 participants ≥ 18 years of age randomized 1: 1 to vaccine or placebo with a median of 7 weeks of follow-up after the second dose supported a favorable safety profile. No specific safety concerns were identified that would preclude the issuance of an EEA “, the information document states.

The Food and Drug Administration (FDA) prepared the document ahead of a scheduled meeting Thursday to consider granting an emergency approval for Moderna’s coronavirus vaccine.

Moderna’s vaccine candidate is currently in Phase 3 clinical trials involving an expanded pool of participants of various ages and health levels. On the 30th. On November 17th, the company released results of the vaccine’s primary efficacy analysis, indicating an efficacy of 94. 1 percent.

The US has received 100 million more doses of the mRNA coronavirus vaccine from the US pharmaceutical company Moderna.

Aside from the US, Moderna has vaccine supply contracts for over 390 million doses with countries such as Canada, Japan, Israel, Japan, Switzerland, Qatar and the United Kingdom, and the European Union.

We are committed to protecting your personal information and have updated our privacy policy to comply with the General Data Protection Regulation (GDPR), a new EU regulation that came into effect on April 25. May 2018 came into force.

Please read our privacy policy. It provides details about the types of data we collect, how we use them and your privacy rights.

Since you already shared your personal information with us when you created your personal account, please check the box below to continue using it:

If you do not want us to process your data further, click here to delete your account.

If you have any questions or concerns about our privacy policy, please contact: privacy @ sputniknews. com.

The fact that users are registered and authorized on Sputnik websites via the user account or accounts in social networks indicates acceptance of these rules.

Users are obliged to comply with national and international laws. Users are required to speak respectfully to the other participants in the discussion, readers, and anyone referred to in the posts.

The website administration has the right to delete comments made in languages ​​other than the language of most of the contents of the website.

The administration has the right to block a user’s access to the site or to delete a user’s account without prior notice if the user violates these rules or if behavior is found that indicates this violation.

Users can initiate the restoration of their account / activate access by contacting the moderators at moderator @ sputniknews. com

If the moderators deem it possible to restore the account / unlock access, this will be done.

In the case of repeated violations of the above rules, which lead to a second block of the user account, access cannot be restored.

Vaccine, Moderna, Food and Drug Administration, Emergency Use Approval

News – UK – Moderna’s COVID-19 Vaccine Shows “No Special Safety Concerns” According to US Federal Regulatory Agency

Ref: https://sputniknews.com